Titan Pharmaceuticals Receives Funding To Develop Combination HIV Therapeutic And Contraceptive Implant For Women In Developing Countries

Titan Pharmaceuticals, Inc.  announced that it has received funding from the Bill & Melinda Gates Foundation to support the demonstration of its ability to deliver a human immunodeficiency virus (“HIV”) preventative therapeutic and a contraceptive from a single implant using its proprietary ProNeura technology, and ensure this technology is accessible to women and adolescent girls in low- and middle-income countries.

Recommended AI News: GrubMarket Expands to Canada through Acquisition of Funtech Software

“Reducing the burden of HIV, while simultaneously increasing access to contraceptive options, could have a major impact on the health of women and adolescent girls in low- and middle-income countries,” said Marc Rubin, M.D., Executive Chairman of Titan. “We believe that our ProNeura platform is uniquely suited to this program, as we have demonstrated the feasibility of long-term delivery of two pharmaceutically active ingredients from a single implant in an earlier development program. The continuous long-term delivery of a contraceptive/antiviral combination has the potential to have a greater public health impact in developing nations, compared with daily dosing of multiple compounds.”

Top Crypto News: “Bitcoin Has No Intrinsic Value”. Then What Gives Bitcoin Value?

[To share your insights with us, please write to sghosh@martechseries.com]